Nordea Lifescience Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 13-12-2024
- Paid Up Capital ₹ 0.10 M
as on 13-12-2024
- Company Age 20 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 100.18%
(FY 2016)
- Profit 96.47%
(FY 2016)
- Ebitda 81.04%
(FY 2016)
- Net Worth -1.88%
(FY 2016)
- Total Assets -49.64%
(FY 2016)
About Nordea Lifescience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kuldeep Jain and Sunaina Jain serve as directors at the Company.
- CIN/LLPIN
U24232DL2004PTC127933
- Company No.
127933
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jul 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Nordea Lifescience Private Limited offer?
Nordea Lifescience Private Limited offers a wide range of products and services, including Cleaning Liquids & Wipes, Disinfectant Spray, Common Disease Medicines, Injectable Products, Hand Sanitizer & Disinfectant, Alcohol Based Hand Sanitizer, Hand Sanitizers & Personal Hygiene, Wet Wipes.
Who are the key members and board of directors at Nordea Lifescience?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kuldeep Jain  | Director | 28-Jul-2004 | Current |
| Sunaina Jain | Director | 11-Aug-2008 | Current |
Financial Performance of Nordea Lifescience.
Nordea Lifescience Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 100.18% increase. The company also saw a substantial improvement in profitability, with a 96.47% increase in profit. The company's net worth dipped by a decrease of 1.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nordea Lifescience?
In 2016, Nordea Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Orange Pharma Private LimitedActive 20 years 10 monthsKuldeep Jain and Sunaina Jain are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nordea Lifescience?
Unlock and access historical data on people associated with Nordea Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nordea Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nordea Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
